Reuters logo
2 months ago
BRIEF-Novartis says Kisqali data reinforce use in breast cancer
June 2, 2017 / 5:35 AM / 2 months ago

BRIEF-Novartis says Kisqali data reinforce use in breast cancer

1 Min Read

June 2 (Reuters) - Novartis Ag

* Novartis presents updated data that reinforce the efficacy and safety of Kisqali (ribociclib) plus letrozole as a first-line option for hr+/her2- advanced or metastatic breast cancer

* Says Kisqali plus letrozole demonstrated median progression-free survival (PFS) of 25.3 months compared to 16.0 months for letrozole alone

* Says patients on Kisqali plus letrozole maintained overall health-related quality of life compared to those treated with letrozole alone, and no new safety concerns have been identified Source text for Eikon: [here ]

Further company coverage: (Reporting by John Miller)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below